How to Stack SS-31 + MOTS-C (Exact Dosing Protocol)
Your mitochondria run on a membrane that most people have never heard of, and almost everything about how SS-31 and MOTS-c work comes back to that membrane and what happens when it starts to fail.
The inner mitochondrial membrane is where your cells actually convert fuel into energy, and it is studded with protein complexes that pass electrons down a chain to generate something called ATP, which is the molecule your body uses to power almost every biological process you have. That chain only works when the membrane stays tightly organized, when the proteins sit at the right angles and distances, and when a phospholipid called cardiolipin holds everything in place.
Cardiolipin is not a receptor. It is a structural fat molecule, the molecular scaffolding that keeps the electron transport chain assembled and functional, and it is uniquely abundant in the inner mitochondrial membrane because that is where it is needed most.
As you age, cardiolipin oxidizes. The structure loosens. The protein complexes drift. The chain becomes inefficient, electrons leak out before reaching their destination, and those leaked electrons react with oxygen to form something called reactive oxygen species, or ROS, which is essentially oxidative byproduct that damages the membrane further. It is a cycle that compounds over time.
That is the problem SS-31 was designed to solve.
SS-31, also called elamipretide, is a small peptide that concentrates around five thousand fold at the inner mitochondrial membrane because it has a specific affinity for cardiolipin. It does not bind a receptor the way most drugs do. It binds the structural molecule itself, which means there is no mechanism by which your cells could downregulate their response to it. There is nothing to desensitize.
This is why the cycling logic that gets applied to most peptides does not translate directly to SS-31. A 168-week continuous human trial in patients with Barth syndrome, a mitochondrial cardiomyopathy, showed progressive improvement across the entire period with no attenuation of effect. Three years of daily dosing and the benefit kept building. That is the signature of structural repair rather than receptor stimulation.
The dosing question is also cleaner than people assume. A phase 2 trial compared 4 milligrams against 40 milligrams and found no functional advantage at the higher dose. When a peptide concentrates five thousand fold at its target, the saturation point arrives quickly, and doses above that threshold are not reaching a part of the cell that the lower dose missed. The practical range is 1 to 5 milligrams daily, and the data does not support pushing beyond that ceiling.
MOTS-c operates through an entirely different mechanism, which is part of why this stack makes sense in the first place.
MOTS-c is a peptide your mitochondria actually produce on their own. It is encoded in the mitochondrial genome, not the nuclear genome, which makes it unusual among signaling molecules, and its job is to act as a messenger that travels from the mitochondria to the nucleus to regulate how the cell responds to metabolic stress.
The mechanism runs through something called AMPK activation, which is the cellular sensor that detects low energy states and triggers adaptation, combined with downstream effects on PGC-1 alpha, which is the master regulator of mitochondrial biogenesis and quality control. When MOTS-c activates this pathway, the cell does not just respond to the immediate signal. It changes which genes are expressed and those changes persist.
This is the key difference between MOTS-c and SS-31 in terms of how you dose them. SS-31 needs to be present continuously because the membrane needs ongoing structural support and the peptide clears in roughly two hours. MOTS-c clears quickly too, but it works by triggering a cascade, and the cascade keeps running after the peptide is gone.
A study in Nature Communications tested whether three-times-weekly dosing could maintain the benefits established by daily loading, and it did. Age-dependent physical decline was blunted, muscle homeostasis was preserved, and mitochondrial function remained improved on a Monday, Wednesday, Friday schedule. The frequency is not arbitrary. It is the minimum effective exposure to keep the gene expression effects sustained.
More recent work published in Free Radical Biology and Medicine showed that MOTS-c improves intrinsic mitochondrial efficiency through this PGC-1 alpha and AMPK pathway without simply increasing mitochondrial content, and it reduces ROS production in the process. That last detail matters because it means MOTS-c is improving the quality of mitochondrial output, not just adding more mitochondria to compensate for inefficient ones.
So when you put these two together, SS-31 is stabilizing and repairing the structural architecture that the electron transport chain depends on, and MOTS-c is signaling the cell to improve how it manages that architecture and reduce the oxidative damage that degrades it. The mechanisms do not overlap. They address adjacent problems in the same system.
No human study has tested this specific combination. The closest published data comes from aged mouse models pairing SS-31 with NMN, which demonstrated synergistic improvements in cardiac metabolism beyond what either compound produced alone. That result is suggestive but not directly transferable. The reasoning behind the MOTS-c and SS-31 stack comes from the non-overlapping mechanisms and the individual efficacy data for each, not from a combination trial that does not yet exist.
The practical protocol is SS-31 at 1 to 5 milligrams daily and MOTS-c at 5 to 15 milligrams per week split across three days. A reasonable starting point for most people is 2 milligrams of SS-31 daily and 10 milligrams of MOTS-c per week, with both doses cut in half if you are new to either compound.
The cycling question deserves a direct answer. The recommendation of 8 to 12 weeks on and 4 to 8 weeks off is precautionary, not mechanistically derived. SS-31 has no desensitization pathway and showed no tolerance across 168 weeks of human data. MOTS-c is endogenous and has no negative feedback loop analogous to what you see with exogenous testosterone. Animal research administered it continuously for the lifespan of the subjects with sustained benefit. The cycle is a hedge against long-term human data we do not yet have at these specific doses, and you should treat it that way rather than as a pharmacological requirement.
The deeper point is this: most of the cycling logic people apply to peptides was developed for compounds that work through receptor binding, where sustained exposure eventually blunts the receptor response. When a compound works through structural repair or durable gene expression changes, the rules are different, and applying receptor-based logic to a structural molecule is a category error that will lead you to underdose something that is actually working.
References
- Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a mitochondrial cardiomyopathy. Genetics in Medicine. 2024;267:101133. 168-week continuous SS-31 at 40mg daily with progressive improvement and no tolerance. Source
- Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020;265:429-437. 4mg vs 40mg comparison: 40mg showed no advantage over 4mg. Source
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. 3x/week maintenance dosing preserved all benefits after daily loading. Source
- Gudiksen A, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner. Free Radical Biology and Medicine. 2026;246:682-696. MOTS-C improves mitochondrial quality without increasing content, reduces ROS. Source
- Whitson JA, et al. SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020;1910:e13213. Closest published combination data: SS-31 + NMN synergy in aged mice. Source
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Original MOTS-C dosing data: 0.5mg/kg chronic, 5mg/kg acute in mice. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.